Nurix Therapeutics Inc (NRIX)
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and antibody-based therapies for cancer, inflammatory disorders, and other diseases. Its pipeline includes NX-5948, an orally available BTK degrader being studied in Phase 2 trials for relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, another BTK degrader in Phase 1a/1b studies for relapsed or refractory B-cell malignancies; and NX-1607, an orally available CBL-B inhibitor in Phase 1a/1b trials for immuno-oncology indications. The company is also developing NX-0479/GS-6791, an IRAK4 degrader being evaluated for rheumatoid arthritis and other inflammatory conditions. Nurix has strategic collaboration agreements with Gilead Sciences, Sanofi, and Pfizer for the co-development and co-commercialization of multiple drug candidates. The company, formerly known as Nurix Inc., adopted its current name in October 2018 and is headquartered in Brisbane, California.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-NRIX
|
$26.58
|
3.5% Upside
|
Fair
|
$33.93
|
32.2% Upside
|
Undervalued
|
Fair
|
0.0%
|
October 9, 2026
|
6.5x
|
71.7x
|
2.664 B
|
2.252 B
|
2.2%
|
76.7%
|
7.5
|
89.2%
|
